Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 892 participants.
Also called NCT02836704
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 892 participants
- Sponsor
- Registry
-
NCT02836704
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02836704. Randomized; no masking; primary purpose treatment. Start 2016-09-09 (actual); primary completion 2018-04-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- INSULIN GLARGINE
- Intervention (Drug)
- metformin
- Intervention (Drug)
- acarbose
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02836704- Content hash
c94926d675ec3d5ae150471faabd53221b440cb360848ed48c5bfeddbbe6ab78